Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2018-10-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于会计政策及会计估计变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding changes in accounting policies and accounting estimates. It references specific accounting standards and regulatory notices issued by the Ministry of Finance and the Shenzhen Stock Exchange. The document details the nature of the changes, their impact on financial statements, and the approval process by the board and supervisory committee. It does not contain full financial statements or comprehensive financial performance data but rather focuses on policy changes and their rationale. The document length is under 5,000 characters and is structured as an announcement rather than a full report. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2018-10-28 Chinese
2018年第三季度报告正文
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2018 Third Quarter Report" of Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed financial data and analysis for the third quarter of 2018, including balance sheet items, income statement figures, cash flow information, shareholder data, and management commentary on financial performance and business activities during the quarter. The length of the document (13,684 characters) and the presence of substantive financial statements and detailed financial metrics confirm it is a comprehensive financial report for a period shorter than a full fiscal year. The document is not an announcement or a brief summary but a full quarterly report with actual financial data and analysis. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2018
2018-10-28 Chinese
关于获得雷帕霉素药物洗脱球囊独家许可权暨子公司对外投资的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acquisition of exclusive licensing rights for a drug-eluting balloon and progress on a subsidiary's external investment. It details a board meeting resolution approving the investment and subsequent shareholding changes in a target company. The content focuses on capital investment and shareholding changes rather than financial results or regulatory certifications. The document length is short (750 characters), and it is an announcement of a financing/investment activity rather than a full report. Therefore, it fits best under Capital/Financing Update (CAP).
2018-10-24 Chinese
关于子公司获得重组胰高血糖素样肽-1-Fc融合蛋白注射液药物临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding its subsidiary obtaining clinical trial approval for a drug from the National Medical Products Administration (China's drug regulatory authority). The text includes details about the drug, its clinical trial approval, and regulatory compliance statements. The document length is short (1182 characters) and it is an announcement of a regulatory approval event, not a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report but an announcement of a regulatory milestone. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-10-24 Chinese
关于控股股东股权解除质押及质押的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Shenzhen Xintai Pharmaceutical Co., Ltd. regarding the release and new pledging of shares held by its controlling shareholder. It details the number of shares released from pledge, newly pledged shares, pledge dates, pledgees, and the proportion of shares involved. The document includes tables with specific shareholding and pledge data, mentions regulatory compliance, and confirms no change in control. There is no financial performance data, no discussion of earnings, no management commentary, and no mention of annual or interim reports. The content is focused on share pledge status and related shareholder information. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share pledges.
2018-10-19 Chinese
关于获得S086片药物临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a clinical trial approval for a new drug (S086). It contains no financial data, no detailed financial performance, no management discussion of financial results, and no regulatory certifications or filings related to financial reports. The document is an official announcement about a regulatory approval related to drug development, which is a general regulatory announcement. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a report publication announcement since it is not announcing the release of a report but rather a regulatory approval. Therefore, the best fitting category is Regulatory Filings (RNS).
2018-10-12 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.